Woodcock J M, Andrews J M, Boswell F J, Brenwald N P, Wise R
Department of Microbiology, City Hospital NHS Trust, Birmingham, United Kingdom.
Antimicrob Agents Chemother. 1997 Jan;41(1):101-6. doi: 10.1128/AAC.41.1.101.
The in vitro activity of BAY 12-8039, a new fluoroquinolone, was studied in comparison with those of ciprofloxacin, trovafloxacin (CP 99,219), cefpodoxime, and amoxicillin-clavulanate against gram-negative, gram-positive, and anaerobic bacteria. Its activity against mycobacteria and chlamydia was also investigated. BAY 12-8039 was active against members of the family Enterobacteriaceae (MIC at which 90% of strains tested were inhibited [MIC90S] < or = 1 microgram/ml, except for Serratia spp. MIC90 2 microgram/ml), Neisseria spp. (MIC90S, 0.015 microgram/ml), Haemophilus influenzae (MIC90, 0.03 microgram/ml), and Moraxella catarrhalis (MIC90, 0.12 micrgram/ml), and these results were comparable to those obtained for ciprofloxacin and trovafloxacin. Against Pseudomonas aeruginosa, the quinolones were more active than the beta-lactam agents but BAY 12-8039 was less active than ciprofloxacin. Strains of Stenotrophomonas maltophilia were fourfold more susceptible to BAY 12-8039 and trovafloxacin (MIC90S, 2 micrograms/ml) than to ciprofloxacin. BAY 12-8039 was as active as trovafloxacin but more active than ciprofloxacin against Streptococcus pneumoniae (MIC90, 0.25 microgram/ml) and methicillin-susceptible Staphylococcus auerus (MIC90S, 0.12 micrograms/ml). The activity of BAY 12-8039 against methicillin-resistant S. aureus (MIC90, 2 micrograms/ml) was lower than that against methicillin-susceptible strains. BAY 12-8039 was active against anaerobes (MIC90S < or = 2 micrograms/ml), being three- to fourfold more active against Bacteroides fragilis, Prevotella spp., and Clostridium difficile than was ciprofloxacin. Against Mycobacterium tuberculosis, BAY 12-8039 exhibited activity comparable to that of rifampin (MICs < or = 0.5 micrograms/ml). Against Chlamydia trachomatis and Chlamydia pneumoniae BAY 12-8039 was more active (MICs < or = 0.12 microgram/ml) than either ciprofloxacin or erythromycin and exhibited a greater lethal effect than either to these two agents. The protein binding of BAY 12-8039 was determined at 1 and 5 micrograms/ml as 30 and 26.4%, respectively. The presence of human serum (at 20 or 70%) had no marked effect on the in vitro activity of BAY 12-8039.
对新型氟喹诺酮类药物BAY 12 - 8039的体外活性进行了研究,并与环丙沙星、曲伐沙星(CP 99,219)、头孢泊肟和阿莫西林 - 克拉维酸针对革兰氏阴性菌、革兰氏阳性菌和厌氧菌的活性进行了比较。还研究了其对分枝杆菌和衣原体的活性。BAY 12 - 8039对肠杆菌科成员具有活性(90%受试菌株被抑制时的最低抑菌浓度[MIC90s]≤1微克/毫升,除沙雷氏菌属,MIC90为2微克/毫升)、奈瑟菌属(MIC90s,0.015微克/毫升)、流感嗜血杆菌(MIC90,0.03微克/毫升)和卡他莫拉菌(MIC90,0.12微克/毫升),这些结果与环丙沙星和曲伐沙星的结果相当。对于铜绿假单胞菌,喹诺酮类药物比β - 内酰胺类药物更具活性,但BAY 12 - 8039的活性低于环丙沙星。嗜麦芽窄食单胞菌菌株对BAY 12 - 8039和曲伐沙星(MIC90s,2微克/毫升)的敏感性比对环丙沙星高四倍。BAY 12 - 8039对肺炎链球菌(MIC90,0.25微克/毫升)和甲氧西林敏感金黄色葡萄球菌(MIC90s,0.12微克/毫升)的活性与曲伐沙星相当,但比环丙沙星更具活性。BAY 12 - 8039对耐甲氧西林金黄色葡萄球菌(MIC90,2微克/毫升)的活性低于对甲氧西林敏感菌株的活性。BAY 12 - 8039对厌氧菌具有活性(MIC90s≤2微克/毫升),对脆弱拟杆菌、普雷沃菌属和艰难梭菌的活性比环丙沙星高3至4倍。对于结核分枝杆菌,BAY 12 - 8039表现出与利福平相当的活性(MICs≤0.5微克/毫升)。对于沙眼衣原体和肺炎衣原体,BAY 12 - 8039比环丙沙星或红霉素更具活性(MICs≤0.12微克/毫升),并且对这两种药物的致死作用更强。BAY 12 - 8039在1微克/毫升和5微克/毫升时的蛋白结合率分别为30%和26.4%。人血清(20%或70%)的存在对BAY 12 - 8039的体外活性没有明显影响。